Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.

doi:10.1007/s00280-021-04247-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.

Cancer chemotherapy and pharmacology - 1 May 2021

Liu Duo, Li Xuehua, Li Xiang, Wang Huiqi, Dong Mei

Abstract excerpt

OBJECTIVES: The aim of this study was to test whether CES1, UMPS, DPYS and TPYS polymorphisms influence the outcomes of gastroenteric cancer patients. METHODS: We consecutively enrolled 338 patients who were diagnosed with colorectal and gastric cancer from January 2016 to December 2018 at the Harbin Medical University Cancer Hospital, China. RESULTS: We found that the patients with CES1 rs7187684 CC genotype had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Carboxylic Ester Hydrolases

Share to Colorectal Neoplasms

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Stomach Neoplasms

Share to Young Adult

Source

Open in PubMed

Identifiers

PMID: 33586000
DOI: 10.1007/s00280-021-04247-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.PMID 33586000Read ↗

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.Semantic proximity Read ↗

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Semantic proximity Read ↗

Pharmacogenomic assessment of carboxylesterases 1 and 2.Semantic proximity Read ↗

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.Semantic proximity Read ↗

Implication of TYMP genetic variation on the prognosis of patients with colorectal cancer who received capecitabine-based adjuvant chemotherapy after surgical resection: a real-world exploratory studySemantic proximity Read ↗

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.Semantic proximity Read ↗

Colorectal cancer in Chinese patients: current and emerging treatment optionsSemantic proximity Read ↗

The Impact of GST Genetic Polymorphisms on the Response to Oxaliplatin-Based Chemotherapy and Survival Prognosis in Gastric Cancer PatientsSemantic proximity Read ↗

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.